On November 8, 2021, Oceanpine Capital announces the promotion of Ms. Rachel Yu as a partner of Oceanpine Capital. Rachel focuses on investment and research and development in the medical industry, and has nearly 20 years of experience in fund management, equity investment, secondary market and new drug research and development. In the future, Ms. Yu will continue to lead the Oceanpine Capital Medical Group to explore more high-quality projects to help Oceanpine Capital's development.
As a Partner, Rachel is focused on investment and research in the healthcare industry. As a veteran of the industry with extensive network and resources, she has nearly 20 years’ experience working in equity investment, secondary market and new drug research and development in both China and the US.
Prior to joining Oceanpine Capital, Rachel had worked as a Partner of CR Life Star Fund and Managing Director of Healthcare and Life Sciences of China Renaissance Capital for over seven years. She had led nearly 30 equity investments, private placements, and IPO deals with a total transaction amount of more than $3 billion over there. Rachel also worked for Gerson Lehrman Group as a Vice President, Head of Research in Beijing and Head of China's Healthcare Practice.
Prior to that, Rachel had worked in the U.S. for more than ten years and served as an Equity Research Analyst of U.S. Healthcare industry for Deutsche Bank and other investment banks and was responsible for U.S. life science company equity research. She had also worked in the new drug development department of Genentech for 5 years, responsible for early target discovery and pre-clinical research and development.
Rachel holds an MBA from the University of Chicago, an MS degree in pharmacology from the University of Missouri, and a B.A. degree in Pharmaceutical Science from Guangdong Pharmaceutical University.
Source: Oceanpine Capital
